Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/19278
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTijani, M-
dc.contributor.authorMunis, AM-
dc.contributor.authorPerry, C-
dc.contributor.authorSanber, K-
dc.contributor.authorFerraresso, M-
dc.contributor.authorMukhopadhyay, T-
dc.contributor.authorThemis, M-
dc.contributor.authorNisoli, I-
dc.contributor.authorMattiuzzo, G-
dc.contributor.authorCollins, MK-
dc.contributor.authorTakeuchi, Y-
dc.date.accessioned2019-10-09T10:07:00Z-
dc.date.available2018-08-07-
dc.date.available2019-10-09T10:07:00Z-
dc.date.issued2018-08-07-
dc.identifier.citationMolecular Therapy - Methods and Clinical Development, 2018, 10 pp. 303 - 312en_US
dc.identifier.issn2329-0501-
dc.identifier.issnhttp://dx.doi.org/10.1016/j.omtm.2018.07.013-
dc.identifier.urihttp://bura.brunel.ac.uk/handle/2438/19278-
dc.description.abstractRetroviral and lentiviral vectors often use the envelope G protein from the vesicular stomatitis virus Indiana strain (VSVind.G). However, lentivector producer cell lines that stably express VSVind.G have not been reported, presumably because of its cytotoxicity, preventing simple scale-up of vector production. Interestingly, we showed that VSVind.G and other vesiculovirus G from the VSV New Jersey strain (VSVnj), Cocal virus (COCV), and Piry virus (PIRYV) could be constitutively expressed and supported lentivector production for up to 10 weeks. All G-enveloped particles were robust, allowing concentration and freeze-thawing. COCV.G and PIRYV.G were resistant to complement inactivation, and, using chimeras between VSVind.G and COCV.G, the determinant for complement inactivation of VSVind.G was mapped to amino acid residues 136–370. Clonal packaging cell lines using COCV.G could be generated; however, during attempts to establish LV producer cells, vector superinfection was observed following the introduction of a lentivector genome. This could be prevented by culturing the cells with the antiviral drug nevirapine. As an alternative countermeasure, we demonstrated that functional lentivectors could be reconstituted by admixing supernatant from stable cells producing unenveloped virus with supernatant containing envelopes harvested from cells stably expressing VSVind.G, COCV.G, or PIRYV.G.en_US
dc.description.sponsorshipNIBSC; EPSRC; UCL Cancer Institute Research Trust;en_US
dc.format.extent303 - 312-
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.subjectLentivectoren_US
dc.subjectVesiculovirus Gen_US
dc.subjectStable packagingen_US
dc.titleLentivector Producer Cell Lines with Stably Expressed Vesiculovirus Envelopesen_US
dc.typeArticleen_US
dc.identifier.doihttp://dx.doi.org/10.1016/j.omtm.2018.07.013-
dc.relation.isPartOfMolecular Therapy - Methods and Clinical Development-
pubs.publication-statusPublished-
pubs.volume10-
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdf1.64 MBAdobe PDFView/Open


Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.